SA518391908B1 - مرهم يشتمل على مركب أوكسازول محدد - Google Patents

مرهم يشتمل على مركب أوكسازول محدد

Info

Publication number
SA518391908B1
SA518391908B1 SA518391908A SA518391908A SA518391908B1 SA 518391908 B1 SA518391908 B1 SA 518391908B1 SA 518391908 A SA518391908 A SA 518391908A SA 518391908 A SA518391908 A SA 518391908A SA 518391908 B1 SA518391908 B1 SA 518391908B1
Authority
SA
Saudi Arabia
Prior art keywords
ointment
oxazole compound
specific oxazole
specific
compound
Prior art date
Application number
SA518391908A
Other languages
English (en)
Inventor
ماتسوموتو كنجو
أوكادا مينورو
كاناي ناوهيكو
كوياما نوريوكي
ماتسوشيتا هيتوشي
موراكامي يوشيهيرو
يوكي يوهي
Original Assignee
اوتسوكا فارماسيوتيكال كو.، ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اوتسوكا فارماسيوتيكال كو.، ليمتد filed Critical اوتسوكا فارماسيوتيكال كو.، ليمتد
Publication of SA518391908B1 publication Critical patent/SA518391908B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مرهم ointment. يشتمل المرهم بشكل مستقر على مركب أوكسازول oxazole حيث يكون له نشاط تثبيطي inhibitory activity معين ضد PDE4 ويتم عرضه بواسطة الصيغة التالية (11). يمكن امتصاص المرهم ointment بفعالية في الجلد skin.
SA518391908A 2015-12-28 2018-06-27 مرهم يشتمل على مركب أوكسازول محدد SA518391908B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015256784 2015-12-28
PCT/JP2016/088843 WO2017115780A1 (en) 2015-12-28 2016-12-27 Ointment

Publications (1)

Publication Number Publication Date
SA518391908B1 true SA518391908B1 (ar) 2022-06-05

Family

ID=57851287

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518391908A SA518391908B1 (ar) 2015-12-28 2018-06-27 مرهم يشتمل على مركب أوكسازول محدد

Country Status (16)

Country Link
US (3) US10588893B2 (ar)
EP (1) EP3397619B1 (ar)
JP (3) JP6873128B2 (ar)
KR (2) KR20240034867A (ar)
CN (1) CN108473448A (ar)
AU (1) AU2016382036B2 (ar)
CA (1) CA3009734A1 (ar)
DK (1) DK3397619T3 (ar)
ES (1) ES2811849T3 (ar)
HK (1) HK1255187A1 (ar)
MY (1) MY197975A (ar)
PH (1) PH12018501346A1 (ar)
SA (1) SA518391908B1 (ar)
SG (2) SG10201912634QA (ar)
TW (1) TWI726027B (ar)
WO (1) WO2017115780A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020019377A2 (pt) 2018-04-04 2021-01-05 Otsuka Pharmaceutical Co., Ltd. Cristal de composto oxazol
JP7051968B2 (ja) * 2019-10-09 2022-04-11 大塚製薬株式会社 オキサゾール化合物結晶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419963B1 (en) * 2001-04-22 2002-07-16 Sarfaraz K Niazi Composition and method for the treatment of diaper rash using natural products
US7655717B2 (en) * 2002-07-17 2010-02-02 Mary J. Goulbourne Ointment composition for treating decubitus ulcers and methods for its making and its use
WO2004073680A1 (ja) * 2003-02-21 2004-09-02 Shionogi & Co., Ltd. 液滴分散型軟膏剤
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
US8575189B2 (en) * 2008-10-08 2013-11-05 Takata Seiyaku Co., Ltd. Tacrolimus preparation for external applications
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
JP5965187B2 (ja) * 2012-03-30 2016-08-03 小林製薬株式会社 油性軟膏剤
US9181205B2 (en) * 2012-08-30 2015-11-10 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound

Also Published As

Publication number Publication date
ES2811849T3 (es) 2021-03-15
KR102643824B1 (ko) 2024-03-07
KR20240034867A (ko) 2024-03-14
PH12018501346B1 (en) 2019-02-18
JP2023058571A (ja) 2023-04-25
US20200171006A1 (en) 2020-06-04
SG11201805364TA (en) 2018-07-30
AU2016382036A1 (en) 2018-07-12
MY197975A (en) 2023-07-25
US20190000810A1 (en) 2019-01-03
TW201729806A (zh) 2017-09-01
AU2016382036B2 (en) 2021-02-04
SG10201912634QA (en) 2020-02-27
HK1255187A1 (zh) 2019-08-09
US10588893B2 (en) 2020-03-17
NZ743851A (en) 2021-09-24
JP2019503989A (ja) 2019-02-14
WO2017115780A1 (en) 2017-07-06
CA3009734A1 (en) 2017-07-06
JP2021107437A (ja) 2021-07-29
TWI726027B (zh) 2021-05-01
PH12018501346A1 (en) 2019-02-18
EP3397619B1 (en) 2020-07-29
DK3397619T3 (da) 2020-08-24
EP3397619A1 (en) 2018-11-07
US20220117944A1 (en) 2022-04-21
KR20180097672A (ko) 2018-08-31
JP6873128B2 (ja) 2021-05-19
CN108473448A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
ZA201701299B (en) Glycosidase inhibitors
MX2019012096A (es) Inhibidor de melanogenesis que comprende alcohol d-pantotenilico, y cosmetico de blanqueamiento de la piel que contiene el mismo inhibidor de melanogenesis.
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
NZ732799A (en) Picolinamides with fungicidal activity
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2015005694A (es) Administracion de vehiculo compartido.
WO2014160185A3 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
MX2016013894A (es) Composicion para el cuidado del cuero cabelludo.
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
ZA201704116B (en) 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
MY186907A (en) Hair growth agent
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2016012689A (es) Piridin-2-amidas utiles como agonistas del receptor 2 cannabinoide (cb2).
TN2017000097A1 (en) Heterocyclic compound
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MY182845A (en) Dual-bearing reel
SA518391908B1 (ar) مرهم يشتمل على مركب أوكسازول محدد
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
GEP20186893B (en) Pyrazines modulators of gpr6
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.